[{"id":"ca9c53ec-c832-4b1c-9e81-bef149f09451","acronym":"","url":"https://clinicaltrials.gov/study/NCT04060394","created_at":"2021-01-18T19:54:03.680Z","updated_at":"2024-07-02T16:35:09.013Z","phase":"Phase 1/2","brief_title":"Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC","source_id_and_acronym":"NCT04060394","lead_sponsor":"Laekna Limited","biomarkers":" PIK3CA • PTEN • BRCA","pipe":" | ","alterations":" PTEN mutation • BRCA mutation","tags":["PIK3CA • PTEN • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone • afuresertib (LAE002) • LAE001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 09/13/2019","start_date":" 09/13/2019","primary_txt":" Primary completion: 12/27/2023","primary_completion_date":" 12/27/2023","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2024-04-18"},{"id":"8a933fa1-ad72-4365-92d4-ccb50f41d3ea","acronym":"PROFECTA-II","url":"https://clinicaltrials.gov/study/NCT04374630","created_at":"2021-01-18T21:08:03.631Z","updated_at":"2024-07-02T16:35:15.070Z","phase":"Phase 2","brief_title":"Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian","source_id_and_acronym":"NCT04374630 - PROFECTA-II","lead_sponsor":"Laekna Limited","biomarkers":" BRCA1 • BRCA2 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PTEN mutation","tags":["BRCA1 • BRCA2 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • afuresertib (LAE002)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-03-13"},{"id":"fae174c0-98ea-47ef-93cf-33fa869c7950","acronym":"","url":"https://clinicaltrials.gov/study/NCT05390710","created_at":"2022-05-25T12:57:02.573Z","updated_at":"2024-07-02T16:35:21.609Z","phase":"Phase 1","brief_title":"PhI to Solid Tumors and PhII to Locally Advanced or mTNBC","source_id_and_acronym":"NCT05390710","lead_sponsor":"Laekna Limited","biomarkers":" HER-2 • PD-L1 • ER • PGR • PTEN • BRCA • PI3K","pipe":" | ","alterations":" PD-L1 expression • PGR expression","tags":["HER-2 • PD-L1 • ER • PGR • PTEN • BRCA • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • afuresertib (LAE002) • LAE005"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/12/2021","start_date":" 06/12/2021","primary_txt":" Primary completion: 12/11/2023","primary_completion_date":" 12/11/2023","study_txt":" Completion: 12/11/2023","study_completion_date":" 12/11/2023","last_update_posted":"2024-01-31"},{"id":"ff5bc58c-ee75-4fcb-9b27-1953531ffbb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05383482","created_at":"2022-05-20T18:58:22.901Z","updated_at":"2024-07-02T16:35:39.188Z","phase":"Phase 1/2","brief_title":"Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1","source_id_and_acronym":"NCT05383482","lead_sponsor":"Laekna Limited","biomarkers":" HER-2 • KRAS • ALK • PTEN • PI3K","pipe":" | ","alterations":" ALK rearrangement • EGFR wild-type • KRAS wild-type • RAS wild-type • ALK negative","tags":["HER-2 • KRAS • ALK • PTEN • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • EGFR wild-type • KRAS wild-type • RAS wild-type • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel • afuresertib (LAE002)"],"overall_status":"Recruiting","enrollment":" Enrollment 167","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-23"},{"id":"83c3d049-a043-4270-a4ae-afb2afbe7faf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04851613","created_at":"2021-04-20T14:55:45.893Z","updated_at":"2024-07-02T16:35:46.262Z","phase":"Phase 1","brief_title":"Study Evaluating Efficacy \u0026 Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT04851613","lead_sponsor":"Laekna LLC","biomarkers":" HER-2 • PIK3CA • PTEN","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • PGR expression","tags":["HER-2 • PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • afuresertib (LAE002)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 04/27/2023","primary_completion_date":" 04/27/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-06-07"},{"id":"5bd55a57-00c4-454c-913f-99248d2d5801","acronym":"","url":"https://clinicaltrials.gov/study/NCT01653912","created_at":"2021-01-18T07:07:50.341Z","updated_at":"2024-07-02T16:37:11.919Z","phase":"Phase 1/2","brief_title":"Dose-finding Study in Platinum-Resistant Ovarian Cancer","source_id_and_acronym":"NCT01653912","lead_sponsor":"Accenture","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • afuresertib (LAE002)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2018-04-02"},{"id":"51b61790-d1b6-4248-b413-2bff644f26b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01476137","created_at":"2021-01-18T06:09:32.727Z","updated_at":"2024-07-02T16:37:16.475Z","phase":"Phase 1/2","brief_title":"A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers","source_id_and_acronym":"NCT01476137","lead_sponsor":"GlaxoSmithKline","biomarkers":" HER-2 • KRAS • ER • PGR","pipe":" | ","alterations":" KRAS mutation • HER-2 negative","tags":["HER-2 • KRAS • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • afuresertib (LAE002)"],"overall_status":"Completed","enrollment":" Enrollment 335","initiation":"Initiation: 10/26/2011","start_date":" 10/26/2011","primary_txt":" Primary completion: 03/12/2013","primary_completion_date":" 03/12/2013","study_txt":" Completion: 03/12/2013","study_completion_date":" 03/12/2013","last_update_posted":"2017-11-13"},{"id":"2a3c9661-2751-40ec-b7b2-8e744a9c1594","acronym":"","url":"https://clinicaltrials.gov/study/NCT02240212","created_at":"2021-01-18T12:34:13.311Z","updated_at":"2024-07-02T16:37:23.539Z","phase":"Phase 1","brief_title":"Study of Afuresertib Combined With Paclitaxel in Gastric Cancer","source_id_and_acronym":"NCT02240212","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • afuresertib (LAE002)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 02/07/2017","primary_completion_date":" 02/07/2017","study_txt":" Completion: 02/07/2017","study_completion_date":" 02/07/2017","last_update_posted":"2017-04-11"}]